The series A round also boasts involvement from Microsoft founder Bill Gates, as Nimbus aims to use computer technology to boost its pharmaceutical research.
SR One and Lilly Ventures, the corporate venturing divisions of multinational pharmaceutical conglomerates GlaxoSmithKline and Eli Lilly respectively, have co-led a $24m series A round for US-based biopharmaceutical company Nimbus Discovery.
Together with venture capital firm Atlas Venture, the two corporate venturing units, the investors also included software comapny Microsfot co-founder Bill Gates, who had previously invested in the seed round in March. His investment was then reported as $10m of an undisclosed sum, funded by Gates, Atlas Venture and…
